Haemonetics

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Haemonetics reports robust Q1 earnings, eyes U.S. growth amid challenges

Haemonetics delivered strong financial performance in Q1 fiscal 2023, driven by robust revenue growth in both the Plasma and Hospital segments. The company's focus on the U.S. market and plans for accelerating growth indicate a positive outlook. However, challenges related to potential cuts in donor payments and varying market conditions outside the U.S. require careful navigation.

Haemonetics Corporation reports robust Q1 fiscal 2024 performance and eyes international expansion

Haemonetics Corporation delivered impressive Q1 fiscal 2024 results, driven by strong revenue growth and improved operating income. The company faces challenges in managing inventory replenishment and potential competition in the autoimmune space. However, opportunities lie in leveraging its robust product portfolio and expanding into international markets.

Haemonetics reports strong Q3 performance, eyes European expansion for growth

Haemonetics delivered robust financial results in Q3, driven by strong revenue growth and strategic initiatives. While facing challenges related to staffing and donor issues, the company is well-positioned to leverage opportunities in expanding markets and technological advancements to drive future growth.

Haemonetics posts robust earnings, eyes global expansion for growth

Haemonetics delivered strong financial results in Q4 2023 and fiscal '23, driven by robust revenue growth and improved earnings per share.
The company's focus on key segments like Plasma, Hospital, Hemostasis, and Vascular Closure positions it well for future growth and market expansion.
While facing challenges such as cost pressures and competitive landscapes, Haemonetics remains optimistic about its ability to drive profitability and market share.
Strategic initiatives, including a modest ramp in market resources and international expansion, present opportunities for Haemonetics to capitalize on market demand and enhance shareholder value.

Haemonetics excels in Q1 '24, eyes growth amid challenges

Haemonetics delivered robust financial performance in Q1 '24, with significant revenue growth and margin expansion.
While facing challenges like product recalls, the company remains focused on value creation and growth acceleration strategies.
Opportunities for growth exist through market scaling, product innovations, and leveraging trial implications for demand growth.

Haemonetics posts robust Q2 earnings, eyes U.S. and international growth

Haemonetics reported strong Q2 results with increased earnings and revenue growth. The company's strategic acquisitions and focus on innovation position it well for future expansion. Challenges in the Blood Center segment require attention, but overall, Haemonetics is poised for continued growth.

Haemonetics posts robust Q3 earnings, eyes growth through innovation

Haemonetics delivered strong financial performance in Q3 2024, driven by revenue growth and operational efficiency improvements.
The company's focus on innovation, technology enhancements, and strategic acquisitions positions it well for future growth and market leadership.
While facing challenges in certain revenue segments, Haemonetics remains poised to capitalize on opportunities for expansion and margin improvement.

Haemonetics posts robust Q4 results, eyes growth through acquisitions

Haemonetics' Q4 2024 performance reflects strong revenue growth and profitability, driven by successful product launches and acquisitions.
While the company faces challenges in margin targets and integration post-acquisitions, strategic focus on innovation and market expansion presents growth opportunities.
Emphasis on non-GAAP measures and regulatory clearances underscores Haemonetics' commitment to transparency and product quality.
Fiscal year 2025 guidance signals a positive outlook for revenue growth and operational efficiency, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

Investors are optimistic about Haemonetics (HAE) given the strength in its Hemostasis Management franchise and increased product uptake.

Here's Why You Should Hold on to Haemonetics (HAE) For Now

BOSTON, April 6, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter fiscal year 2022 financial results at 6:00 am EDT on Tuesday, May 10, 2022. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am EDT on May 10, 2022.

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2022 Results: May 10, 2022

Haemonetics (HAE) has made the NexSys PCS devices available in the United States to ensure timely conversion of the remainder of its major customers to the same by mid-fiscal 2023.

Haemonetics' (HAE) Hospital Business Grows, Cost Ails Stay

BOSTON , March 21, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today announced that James C. D'Arecca will join the Company as Executive Vice President, Chief Financial Officer, effective April 11, 2022.

Haemonetics Appoints James D'Arecca Chief Financial Officer

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?

Haemonetics (HAE) Up 4.4% Since Last Earnings Report: Can It Continue?

Investors are optimistic about Haemonetics (HAE) given strong recovery across businesses and strength in plasma franchise.

Here's Why You Should Retain Haemonetics (HAE) Stock for Now

BOSTON, Feb. 23, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 43rd Annual Institutional Investors Conference on Monday, March 7, 2022, at 9:50 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at: https://kvgo.com/rj-43rd-iic/haemonetics-corporation-march-2022 A replay of the recorded webcast will become accessible 12 hours after the event and will be available for one year on Haemonetics' Investor Relations website.

Haemonetics to Present at Raymond James 43rd Annual Institutional Investors Conference

Haemonetics (HAE) exited the fiscal third quarter with better-than-expected earnings and robust growth across Hospital business, driving the top line.

Haemonetics (HAE) Q3 Earnings Top Estimates, Revenues Miss

The stock price of Haemonetics Corporation (NYSE: HAE) increased by 16.16% in the most recent trading session. This is why it happened.

Haemonetics (HAE) Stock: Why The Price Jumped

Haemonetics Corporation HAE posted Q3 FY22 sales of $259.77 million, +8% Y/Y, missing the consensus of $ $266.74 million. Organic revenue was down 0.8%.

Why Haemonetics Shares Are Trading Higher Today?

Haemonetics Corporation (HAE) CEO Christopher Simon on Q3 2022 Results - Earnings Call Transcript

Haemonetics (HAE) delivered earnings and revenue surprises of 12% and 2.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) Q3 Earnings Beat Estimates

BOSTON, Feb. 8, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal 2022, which ended January 1, 2022, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.

Haemonetics 3rd Quarter Fiscal Year 2022 Earnings Release Available on Investor Relations Website

Haemonetics (HAE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Haemonetics (HAE) Ahead of Earnings?

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Haemonetics (HAE) Expected to Beat Earnings Estimates: Should You Buy?

BOSTON, Jan. 5, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2022 financial results at 6:00 am EST on Tuesday, February 8, 2022. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am EST on February 8, 2022.

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2022 Results: February 8, 2022

Investors are optimistic about Haemonetics (HAE) on a strong recovery across businesses, mainly at Hospital, and the initial Plasma Persona rollouts.

Here's Why You Should Retain Haemonetics (HAE) Stocks for Now

Haemonetics (HAE) revenues increased year over year in the fiscal second quarter, supported by recovery across major businesses, especially Hospital and the initial Plasma Persona rollouts.

Haemonetics (HAE) Q2 Earnings Lag Estimates, Gross Margin Grows

The company broadly meets expectations for its Q2 2022 but trims its full-year guidance.

Why Haemonetics Stock Dived by 15% Today

Haemonetics Corporation's (HAE) CEO Chris Simon on Q2 2022 Results - Earnings Call Transcript

Haemonetics (HAE) delivered earnings and revenue surprises of -4.76% and -2.44%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) Lags Q2 Earnings and Revenue Estimates

BOSTON, Nov. 9, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal 2022, which ended October 2, 2021, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.

Haemonetics 2nd Quarter Fiscal Year 2022 Earnings Release Available on Investor Relations Website

BOSTON, Nov. 9, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that William P. Burke, Executive Vice President, Chief Financial Officer, has decided to retire from the Company.

Haemonetics Announces CFO William P. Burke's Retirement for June 2022

Align Technology

Eli Lilly

Moderna

Phreesia Inc

Vertex Pharmaceuticals

Management's Discussion of Fund Performance1

Eaton Vance Worldwide Health Sciences Fund 2021 Annual Report

BOSTON, Oct. 6, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2022 financial results at 6:00 am EST on Tuesday, November 9, 2021. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am EST on November 9, 2021.

News for Haemonetics Stock (HAE)